IJACT, Volume 3, Issue 2, 2025 ISSN: 2995-5378
http://medicaljournals.eu/index.php/IJACT
INTERNATIONAL JOURNAL OF ALTERNATIVE AND CONTEMPORARY THERAPY

# Hyperprolactinemia and Infertility: New Insights

**Nawras Najah mubark, Shahad Q. Al-Hamadiny**
*Wasit University, College of Science, Department of Forensic Evidence*

**Abstract:** High serum prolactin levels define hyperprolactinemia which exists as a widespread endocrine medical condition. We identify this medical problem as a primary infertility factor since elevated prolactin reduces GnRH signals to cause irregular menstruation cycles and block ovulation and disturb the endometrium function. This paper provides an updated evaluation that explores both the origins and medical manifestation of hyperprolactinemia-associated infertility while discussing diagnosis procedures and treatment options. Research has examined both the mechanisms of GnRH inhibition by kisspeptin neurons while studying advances in treatment with dopamine agonists and surgical interventions and alternative therapeutic approaches. Knowledge about how hyperprolactinemia affects reproductive health stands essential to develop optimal fertility treatments together with superior pregnancy success rates.

**Keywords:** Hyperprolactinemia, Infertility, Pituitary Adenoma, Kisspeptin, Dopamine Agonists, GnRH Suppression, Ovulatory Dysfunction.

## 1. Introduction

Hyperprolactinemia, which is characterized as the anterior pituitary gland's high production of prolactin (PRL), affects 9% to 17% of infertile women. While prolactin is required for lactation, excessive secretion affects reproductive function by blocking GnRH release, which lowers LH and FSH output. These hormonal abnormalities cause ovulatory failure, luteal phase deficiencies, and secondary amenorrhea[1].

The suppression of GnRH by PRL depends on kisspeptin neurons as recent studies demonstrate while creating fresh therapeutic possibilities. This review provides comprehensive information about hyperprolactinemia-related infertility including its causes and physical processes and diagnostic methods and therapeutic approaches. The assessment focuses on current research findings.

## 2.Causes of Hyperprolactinemia

Hyperprolactinemia can arise from physiological, pharmacological, and pathological causes:

### 2.1Physiological Causes

- ✓ Pregnancy and lactation
- ✓ Stress (physical or emotional)
- ✓ Intense exercise
- ✓ Sleep

### 2.2 Pharmacological Causes

Several medications increase PRL levels by inhibiting dopamine (DA) receptors or stimulating prolactin secretion, including:

- ✓ Antipsychotics (e.g., risperidone, haloperidol)
- ✓ Antidepressants (e.g., SSRIs, tricyclic antidepressants)
- ✓ Opioids

Copyright © 2025 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.

- ✓ Estrogen-based contraceptives

### 2.3 Pathological Causes

- ✓ Pituitary adenomas (Prolactinomas)
- ✓ Microadenomas (<10 mm) – More common in women, often asymptomatic
- ✓ Macroadenomas (>10 mm) – May cause headaches, visual disturbances
- ✓ Hypothyroidism (TRH stimulates PRL secretion)
- ✓ Chronic renal failure (reduced PRL clearance)
- ✓ Polycystic ovary syndrome (PCOS) (mild PRL elevations)[2]

## 3. Pathophysiology of Hyperprolactinemia-Induced Infertility

Prolactin regulates reproductive function via its inhibitory effect on GnRH neurons. Elevated PRL suppresses pulsatile GnRH release, leading to:

- ✓ Decreased LH and FSH secretion → Follicular growth impairment
- ✓ Reduced estradiol levels → Luteal phase insufficiency
- ✓ Irregular or absent ovulation → Anovulatory cycles

### 3.1Kisspeptin and GnRH Suppression

Recent findings suggest that kisspeptin-expressing neurons in the hypothalamus mediate PRL-induced suppression of GnRH . Kisspeptin plays a crucial role in GnRH activation, and PRL downregulates kisspeptin expression, exacerbating infertility. Exogenous kisspeptin administration has been shown to restore ovulation in animal models, providing a potential therapeutic strategy[3].

## 4. Clinical Manifestations

The reproductive consequences of hyperprolactinemia include:

- ✓ Irregular menstrual cycles (oligomenorrhea, amenorrhea)
- ✓ Anovulation (leading to infertility)
- ✓ Luteal phase defects (inadequate progesterone production)
- ✓ Galactorrhea (milky nipple discharge in non-lactating women)

## 5. Diagnosis of Hyperprolactinemia

### 5.1 Laboratory Tests

- ✓ Serum PRL levels (normal: <25 ng/mL; hyperprolactinemia: >30 ng/mL)
- ✓ Thyroid function tests (to rule out hypothyroidism)
- ✓ LH, FSH, estradiol levels (to assess ovarian function)

### 5.2Imaging Studies

- ✓ MRI of the pituitary gland – To detect microadenomas or macroadenomas

## 6. Treatment Approaches

### 6.1Dopamine Agonists (DAs)

Dopamine agonists are first-line therapy for hyperprolactinemia. They act by inhibiting PRL secretion via D2 receptor activation, restoring GnRH pulsatility.

- ✓ Bromocriptine (2.5–7.5 mg/day) – Effective but associated with nausea
- ✓ Cabergoline (0.5–1 mg/week) – More potent, fewer side effects [4].

Copyright © 2025 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.

### 6.2Surgical Intervention

Indicated for resistant prolactinomas or medication intolerance. Transsphenoidal surgery can be effective for macroadenomas but carries risks of hypopituitarism.

### 6.3Adjunctive Therapies

- ✓ Kisspeptin administration – Emerging therapy to restore ovulation
- ✓ Gonadotropins or pulsatile GnRH therapy – For DA-resistant cases

## 7. Fertility Outcomes

- ✓ Ovulation restoration in >80% of patients with DA therapy
- ✓ Pregnancy rates of ~53% with bromocriptine, >65% with cabergoline
- ✓ Postpartum resolution occurs in some cases due to hypothalamic-pituitary rebalancing [5].

## 8. Future Directions

1. Kisspeptin-based therapies – Potential alternative to DAs for ovulation induction
2. Gene therapy targeting PRL signaling pathways
3. Improved surgical techniques to reduce recurrence rates in macroprolactinomas

## 9. Conclusion

Hyperprolactinemia is a reversible cause of infertility in women. Advances in our understanding of kisspeptin signaling and new treatment strategies, such as dopamine agonists and GnRH-based therapies, provide hope for improved fertility outcomes. Early diagnosis and targeted therapy remain crucial for successful pregnancy in affected women.

## References

1. Edinoff AN, Silverblatt NS, Vervaeke HE, Horton CC, Girma E, Kaye AD, Kaye A, Kaye JS, Garcia AJ, Neuchat EE, Eubanks TN, Varrassi G, Viswanath O, Urits I. Hyperprolactinemia, Clinical Considerations, and Infertility in Women on Antipsychotic Medications. Psychopharmacol Bull. 2021 Mar 16;51(2):131-148
2. Maiter D. Prolactinoma and pregnancy: From the wish of conception to lactation. Ann Endocrinol (Paris). 2016 Jun;77(2):128-34. doi: 10.1016/j.ando.2016.04.001. Epub 2016 Apr 26. PMID: 27130071
3. Haidenberg-David F, Sidauy-Adissi J, Moscona-Nissan A, Jonguitud-Zumaya E, Fugarolas-Morinelli M, Martinez-Mendoza F, Taniguchi-Ponciano K, Marrero-Rodríguez D, Mercado M. Overview of Hyperprolactinemia: General Approach and Reproductive Health Implications. Arch Med Res. 2024 Dec;55(8):103102. doi: 10.1016/j.arcmed.2024.103102. Epub 2024 Oct 24. PMID: 39454469.
4. Junqueira DR, Bennett D, Huh SY, Casañas I Comabella C. Clinical Presentations of Drug-Induced Hyperprolactinaemia: A Literature Review. Pharmaceut Med. 2023 Mar;37(2):153-166. doi: 10.1007/s40290-023-00462-2. Epub 2023 Feb 17. PMID: 36800148; PMCID: PMC10097739.
5. Kaiser UB. Hyperprolactinemia and infertility: new insights. J Clin Invest. 2012 Oct;122(10):3467-8. doi: 10.1172/jci64455. PMID: 23193578; PMCID: PMC3461927.

Copyright © 2025 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.